Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
The FDA lifted a clinical hold on Filana Therapeutics' IND application, allowing a Phase 2a trial for a TSC-related epilepsy treatment.
Share
Why It Matters
The FDA said Filana can test its epilepsy medicine on patients. This means the company can move forward with its research plan.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.